β_1肾上腺素受体与CYP2D6基因多态性对美托洛尔抗高血压治疗的影响  

Effectes of β_1-adrenergic receptor and CYP2D6 gene polymorphism on metoprolol antihypertension therapy

作　　者：徐承华[1] 杨玉雯[2] 曹蘅[2] 

机构地区：[1]安徽省芜湖市中医院心血管内科 [2]皖南医学院弋矶山医院心血管内科

出　　处：《中国临床药理学与治疗学》2011年第12期1414-1418,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：芜湖市科技计划项目(2008710)

摘　　要：目的:探讨β1肾上腺素受体与CYP2D6基因多态性对美托洛尔抗高血压治疗的影响。方法:将2008年10月至2009年10月在安徽省皖南地区收集的120例原发性高血压患者进行β1肾上腺素能受体(β1-AR)和代谢酶细胞色素2136(CYP2D6)基因多态性检测,将β1-AR 389位携带Arg的118例患者按照CYP2D6基因表型分为弱代谢组(PM组,55例)、中等代谢组(IM组,36例)和强代谢组(EM组,27例),给予相同剂量(100mg/d)美托洛尔,均分2次口服降压治疗,共随访4周,观察血压、心率和不良反应等指标。结果:PM、IM、EM组血压和心率均下降,尤以PM组血压和心率降幅最大,但不良反应发生率明显增加。结论:β1肾上腺素受体和CYP2D6基因多态性与美托洛尔降压疗效有一定相关性。To investigate effects of β1adrenergic receptor and CYP2D6 gene polymorphism on metoprolol antihypertension therapy. METHODS： 120 cases of patients with essential hypertension were detected by β1adrenergic receptor and CYP2D6 gene polymorphism, 118 patients with Arg 389 allele in β1adrenergic receptor gene chosen from 120 essential hypertension patients were divided into three phenotype groups according to CYP2D6 gene mutations： the poor metabolism group（PM, 55 cases）, intermediate metabolism group（IM, 36 cases） and extensive metabolism group（EM, 27 cases）. The subjects of PM, IM and EM were administratedwith metoprolol for the same dose（100 mg/d）, taking orally twiceaday. Blood pressures, heart rates and side effects were observed during 4-week followingup. RESULTS=Blood pressure and heart rate in group PM, IM and EM were decreased, especially, obviously decreased in group PM, however, the incidence of side effect was significantly increased in group PM. CONCLUSlON： The genetic polymorphism of β1adrenergic receptor and CYP2D6 was associated with the efficiency of metoprolol antihypertension therapy.

关 键 词：原发性高血压 Β1肾上腺素受体 CYP2D6 基因多态性 美托洛尔 

分 类 号：R544.1[医药卫生—心血管疾病]